Alpha 2.0
Login Register
» Authors » Naoki Koshimizu

Naoki Koshimizu

Explore the profile of Naoki Koshimizu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 380
Followers 0
Related Specialties
Pulmonary Medicine
General Medicine
Oncology
Top 10 Co-Authors
Takafumi Suda
Mikio Toyoshima
Noriyuki Enomoto
Naoki Inui
Tomoyuki Fujisawa
Koshi Yokomura
Yutaro Nakamura
Shiro Imokawa
Masato Karayama
Yuzo Suzuki
Published In
Nihon Kokyuki Gakkai Zasshi
Respir Med
BMC Pulm Med
Int J Chron Obstruct Pulmon Dis
Respir Investig
Affiliations
Soon will be listed here.
Recent Articles
1.
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registry
Kono M, Enomoto N, Inoue Y, Yasui H, Karayama M, Suzuki Y, et al.
Respir Investig . 2025 Feb; 63(2):216-223. PMID: 39892159
Background: Idiopathic interstitial pneumonias (IIPs) may remain unclassifiable owing to inadequate, nonspecific, or conflicting clinical, radiological, or histopathological findings despite multidisciplinary discussion (MDD). Unclassifiable IIP (UCIIP) is a heterogeneous disease...
2.
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study
Nakayasu H, Karayama M, Enomoto N, Inoue Y, Yasui H, Suzuki Y, et al.
Respir Investig . 2024 Dec; 63(1):138-145. PMID: 39693847
Background: Progressive pulmonary fibrosis (PPF) is a critical concern in interstitial lung disease (ILD) management. The HAL score, which incorporates honeycombing (H), age >75 years (A), and serum lactate dehydrogenase...
3.
Immune checkpoint inhibitor-induced autoimmune limbic encephalitis with positivity for anti-Hu antibodies in a patient with small-cell lung cancer: A case report and literature review
Nakahara L, Matsuura S, Suzuki R, Kawamura A, Nagasaki T, Masuda T, et al.
Respirol Case Rep . 2024 Nov; 12(11):e70070. PMID: 39588329
In recent years, there has been an increasing number of studies on neurological symptoms induced as paraneoplastic neurological syndrome (PNS) or neurological immune-related adverse events (irAEs) in patients treated with...
4.
Factors associated with uncontrolled severe asthma in the biologic era
Yasui H, Oishi K, Nihashi F, Furuhashi K, Fujisawa T, Inoue Y, et al.
Respir Med . 2024 Nov; 236():107881. PMID: 39580034
Background: Despite the development of biologics for severe asthma, individuals with uncontrolled status persist, posing a significant social problem. This multicenter prospective study aimed to identify factors associated with the...
5.
CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study
Enomoto N, Nakai S, Yazawa S, Mochizuka Y, Fukada A, Tanaka Y, et al.
Respir Res . 2024 Sep; 25(1):346. PMID: 39342309
Background: Interstitial pneumonia with autoimmune features (IPAF), which does not meet any of the criteria for connective tissue diseases (CTD), has been attracting an attention in patients with idiopathic interstitial...
6.
Radiological and histopathological features and treatment response by subtypes of interstitial pneumonia with autoimmune features: A prospective, multicentre cohort study
Enomoto N, Yazawa S, Mochizuka Y, Fukada A, Tanaka Y, Naoi H, et al.
Respir Med . 2024 Feb; 224:107577. PMID: 38408707
Background: Patients with idiopathic interstitial pneumonia (IIP) have a favourable prognosis when they have interstitial pneumonia with autoimmune features (IPAF). However, precise IPAF-related findings from high-resolution computed tomography (HRCT) and...
7.
Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease
Fukada A, Fujisawa T, Hozumi H, Koda K, Akamatsu T, Oyama Y, et al.
Arthritis Rheumatol . 2023 Dec; 76(5):796-805. PMID: 38146102
Objective: Interferon-λ3 (IFNλ3) is a cytokine with antiviral functions on barrier surfaces, and it is associated with disease activity in autoimmune diseases. This study assessed the clinical significance of serum...
8.
The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
Matsuura S, Serizawa S, Yamashita R, Morikawa K, Ito Y, Hiramatsu T, et al.
Ann Med . 2023 Apr; 55(1):2196089. PMID: 37043179
Background: Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage...
9.
An autopsy case of disseminated Cunninghamella bertholletiae infection in an immunocompetent patient: a case report
Harada M, Yasuda K, Uruchida K, Yamashita R, Morikawa K, Ito Y, et al.
BMC Pulm Med . 2023 Mar; 23(1):88. PMID: 36932380
Background: Recently, deaths due to mucormycosis in immunocompromised hosts have increased; however, the clinical and pathological features of mucormycosis are not fully understood, especially in view of the associated high...
10.
Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study
Koda K, Enomoto Y, Aoshima Y, Amano Y, Kato S, Hasegawa H, et al.
Ther Adv Chronic Dis . 2022 Jul; 13:20406223221108395. PMID: 35782342
Introduction: Although recent advances in chemotherapy for lung cancer are remarkable, most clinical trials have excluded patients with interstitial lung disease (ILD) due to the concern of developing acute exacerbation...